Literature DB >> 182948

Overdosage with vincristine.

I A Kaufman, F H Kung, H M Koenig, S T Giammona.   

Abstract

Five patients received overdoses of vincristine ranging from 3.5 to 32 mg. Neurotoxicity accounted for most of the complications observed. Peripheral neuropathies, cranial nerve palsies, paralytic ileus, atony of the bladder, hypertension, hypotension, seizures, inappropriate ADH secretion, and severe bone marrow depression were all encountered. Two patients died within 72 hours of the overdose. Another patient died of sepsis 22 days after the overdose. Two patients recovered and were discharged. The three patients who survived longer than a few days showed improvement in the vincristine-induced neuropathy, and the two long-term survivors had essentially complete recovery. It appears that if a patient can be supported through the critical period following an overdose, he can be expected to recover normal neurologic function.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182948     DOI: 10.1016/s0022-3476(76)80416-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  Accidental iatrogenic intoxications by cytotoxic drugs: error analysis and practical preventive strategies.

Authors:  B Zernikow; E Michel; G Fleischhack; U Bode
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

2.  Prolonged gastrointestinal dysmotility in a patient with hemophagocytic lymphohistiocytosis treated with vincristine.

Authors:  T Tomomasa; R Miyazawa; M Kato; M Hoshino; M Tabata; H Kaneko; M Suzuki; T Kobayashi; A Morikawa
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

Review 3.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 4.  Vincristine neurotoxicity. Pathophysiology and management.

Authors:  S S Legha
Journal:  Med Toxicol       Date:  1986 Nov-Dec

5.  Syndrome of inappropriate secretion of antidiuretic hormone secondary to vinblastine overdose.

Authors:  S C Winter; G S Arbus
Journal:  Can Med Assoc J       Date:  1977-11-19       Impact factor: 8.262

6.  Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity.

Authors:  C R Pinkerton; B McDermott; T Philip; P Biron; C Ardiet; H Vandenberg; M Brunat-Mentigny
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Effect of vincristine on gastric motility in conscious rats.

Authors:  H Kaneko; T Tomomasa; T Watanabe; A Takahashi; M Tabata; S Hussein; A Morikawa
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

8.  Clinical trial of folinic acid to reduce vincristine neurotoxicity.

Authors:  D V Jackson; R A McMahan; E K Pope; L D Case; M R Cooper; M K Kaplon; F Richards; J J Stuart; D R White; P J Zekan
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 9.  Hematologic and oncologic complications in the critically ill child.

Authors:  S McIntosh
Journal:  Yale J Biol Med       Date:  1984 Mar-Apr

Review 10.  Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor.

Authors:  Qing-Yan Yang; Ya-Hui Hu; Hong-Li Guo; Ying Xia; Yong Zhang; Wei-Rong Fang; Yun-Man Li; Jing Xu; Feng Chen; Yong-Ren Wang; Teng-Fei Wang
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.